BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study

Diener, Hans Christoph; Barbanti, Piero; Dahlöf, Carl; Reuter, Uwe; Habeck, Julia; Podhorná, Jana

doi:10.1177/0333102410388435

Cited by 198 publications

(129 citation statements)

References 26 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Results from the phase II trial showed that BI 44370 TA 400 mg was similar to eletriptan 40 mg and superior to placebo in the acute treatment of migraine. Studied patients included those who experienced episodic migraine with and without aura and excluded those overusing other abortive medications [86].…”

Section: Cgrp Receptor Antagonistsmentioning

confidence: 99%

Targeting CGRP: A New Era for Migraine Treatment

Goldberg

Silberstein

2015

CNS Drugs

View full text Add to dashboard Cite

Migraine is a highly prevalent headache disease that typically affects patients during their most productive years. Despite significant progress in understanding the underlying pathophysiology of this disorder, its treatment so far continues to depend on drugs that, in their majority, were not specifically designed for this purpose. The neuropeptide calcitonin gene-related peptide (CGRP) has been indicated as playing a critical role in the central and peripheral pathways leading to a migraine attack. It is not surprising that drugs designed to specifically block its action are gaining remarkable attention from researchers in the field with, at least so far, a safe risk profile. In this article, we highlight the evolution from older traditional treatments to the innovative CGRP target drugs that are revolutionizing the way to approach this debilitating neurological disease. We provide a brief introduction on pathophysiology of migraine and details on the characteristic, function, and localization of CGRP to then focus on CGRP receptor antagonists (CGRP-RAs) and CGRP monoclonal antibodies (CGRP mAbs). Key PointsThe neuropeptide calcitonin gene-related peptide (CGRP) has been indicated as playing a critical role in the central and peripheral pathways leading to a migraine attack.Targeting CGRP as a specific therapeutic tool for migraine may offer similar or even better efficacy than currently available treatments without the vasoconstrictive risk factors.Further studies are necessary to determine the exact role of CGRP receptor antagonists and CGRP monoclonal antibodies in migraine with aura, allodynia, and photophobia.

show abstract

Section: Cgrp Receptor Antagonistsmentioning

confidence: 99%

Targeting CGRP: A New Era for Migraine Treatment

Goldberg

Silberstein

2015

CNS Drugs

View full text Add to dashboard Cite

show abstract

“…These include the antagonists olcegepant (BIBN4096BS, [156] (11) (Figure 4 and Table 2), MK 3207 (15) [60] (Figure 5 and Table 2) telcagepant (MK-0974) (16) ( Figure 5 and Table 2), and BI 4370TA [157]. Olcegepant was one of the first CGRP antagonists shown to be effective in the suppression of CGRP induced pain and to inhibit vasodilation without cardiovascular side effects as known for triptans which belong commonly to the medication of migraineurs if they are free of cardiovascular diseases.…”

Section: Cgrp Receptor Ligandsmentioning

confidence: 99%

Neuropeptide Receptors in Pain Circuitries: Useful Targets for CNS Imaging with Non-Peptide Ligands Suitable for PET?

Pissarek¹

2014

WJNS

View full text Add to dashboard Cite

show abstract

“…A second Merck CGRP drug was studied and abandoned. Two other CGRP antagonists, BI 44370 TA and BMS-927711, have recently shown promise [17,18]. CGRP antagonists do not carry the same cardiovascular risk profile as triptans [19].…”

Section: Calcitonin Gene-related Peptide (Cgrp) Receptor Antagonistsmentioning

confidence: 99%

Update on future headache treatments

Nagy

Rapoport

2013

Neurol Sci

View full text Add to dashboard Cite

Headache disorders are common and heterogenous neurologic entities. The complexities of management are further encumbered by the relatively few effective choices for acute and preventive therapies available to the headache specialist to treat these diverse disorders. As advances have been made in uncovering headache pathophysiology, new therapies have surfaced and others are forthcoming. This article will highlight new lines of care in development. There are several novel delivery mechanisms of familiar medications which bypass the limitations of current delivery systems, including the sumatriptan iontophoretic patch Zecuity, the intranasal sumatriptan OptiNose system, the zolmitriptan Rapidfilm orally dissolvable film and the orally inhaled dihydroergotamine Levadex system. New lines of care based upon recently discovered therapeutic targets will also be discussed including calcitonin gene-related peptide (CGRP) receptor antagonists, serotonin receptor agonists, and sphenopalatine ganglion (SPG) intermittent stimulation. Finally, emerging targets for future therapeutics will be explored including transient receptor potential vanilloid (TRPV1) receptor modulators, nitric oxide (NO) antagonists, gap junction modulators, glutamate receptor antagonists, orexin receptor antagonists and prostanoid receptor antagonists. Therapies developing over the next several years will be welcome additions to the headache specialist's armamentarium.

show abstract

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study

Abstract: Efficacy of BI 44370 TA was shown in a dose-dependent manner in the treatment of acute migraine attacks.

Cited by 198 publications

References 26 publications

Targeting CGRP: A New Era for Migraine Treatment

Targeting CGRP: A New Era for Migraine Treatment

Neuropeptide Receptors in Pain Circuitries: Useful Targets for CNS Imaging with Non-Peptide Ligands Suitable for PET?

Update on future headache treatments

Contact Info

Product

Resources

About